Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...

Pfizer said Thursday that it is back in the race to get an effective weight-loss pill to market. The company’s announcement, ...

On the heels of Terns’ positive Phase I results that analysts compared with Lilly’s and Pfizer’s weight loss pills in ...

Terns Pharmaceuticals will advance TERN-601 into Phase II after early-stage data showed the oral therapy led to weight loss ...

Terns Pharmaceuticals said its oral obesity drug reduced weight by an average of 4.9% in an early stage study, joining ...

Competition is brewing for Novo Nordisk and Eli Lilly, two of the world's leading pharmaceutical weight loss companies, according to analysts ... The potential business rivals are Roche, Amgen, Pfizer ...

The ultimate battle may be over which drugmaker can deliver the best, most effective weight loss pill. Earlier this month, Pfizer said that it would be moving ahead with clinical trials for a once ...

On July 11, Pfizer (NYSE: PFE ... it won't have a first-to-market advantage in pill-based weight loss drugs. Nor will it have an efficacy advantage, barring an unexpectedly favorable set of ...

A once-daily pill the biotech is developing helped some people with obesity lose more than 5% of their weight in a month, spurring a stock bump and plans to bring the drug into further testing.

And Pfizer could use the sales boost. The company’s revenue hit $100 billion in 2022 on pandemic-related sales but has since ...

Let's dive in and find out. Pfizer's most discussed weight loss program for the moment is danuglipron, and it's currently in phase 1 clinical trials. The pill is formulated for once-per-day ...

Pfizer Inc is launching a new website to promote and improve access to its health care offerings for migraine and respiratory ...